

# James C Grotta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4151829/publications.pdf>

Version: 2024-02-01

430  
papers

36,263  
citations

2101

100  
h-index

3915

177  
g-index

441  
all docs

441  
docs citations

441  
times ranked

20718  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. <i>Lancet, The</i> , 2004, 363, 768-774.	13.7	2,316
2	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. <i>Lancet, The</i> , 2014, 384, 1929-1935.	13.7	1,971
3	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. <i>Lancet, The</i> , 2010, 375, 1695-1703.	13.7	1,871
4	Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke. <i>New England Journal of Medicine</i> , 2004, 351, 2170-2178.	27.0	1,006
5	Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. <i>Stroke</i> , 1999, 30, 905-915.	2.0	778
6	NX-059 for the Treatment of Acute Ischemic Stroke. <i>New England Journal of Medicine</i> , 2007, 357, 562-571.	27.0	664
7	Combined Intravenous and Intra-Arterial t-PA Versus Intra-Arterial Therapy of Acute Ischemic Stroke. <i>Stroke</i> , 1999, 30, 2598-2605.	2.0	636
8	NX-059 for Acute Ischemic Stroke. <i>New England Journal of Medicine</i> , 2006, 354, 588-600.	27.0	632
9	Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke. <i>Stroke</i> , 2016, 47, 581-641.	2.0	539
10	Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease. <i>American Journal of Human Genetics</i> , 2009, 84, 617-627.	6.2	466
11	Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. <i>Neurology</i> , 2002, 59, 862-867.	1.1	429
12	Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients With Acute Ischemic Stroke. <i>Circulation</i> , 1996, 94, 1167-1174.	1.6	429
13	Serum Glucose Level and Diabetes Predict Tissue Plasminogen Activator-Related Intracerebral Hemorrhage in Acute Ischemic Stroke. <i>Stroke</i> , 1999, 30, 34-39.	2.0	355
14	Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. <i>Stroke</i> , 1998, 29, 18-22.	2.0	349
15	Reperfusion Injury: Demonstration of Brain Damage Produced by Reperfusion after Transient Focal Ischemia in Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 1048-1056.	4.3	342
16	High Rate of Complete Recanalization and Dramatic Clinical Recovery During tPA Infusion When Continuously Monitored With 2-MHz Transcranial Doppler Monitoring. <i>Stroke</i> , 2000, 31, 610-614.	2.0	338
17	Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L). <i>Stroke</i> , 2010, 41, 2265-2270.	2.0	324
18	Hematoma resolution as a target for intracerebral hemorrhage treatment: Role for peroxisome proliferator-activated receptor $\beta$ in microglia/macrophages. <i>Annals of Neurology</i> , 2007, 61, 352-362.	5.3	319

#	ARTICLE	IF	CITATIONS
19	Clinical Features of Moyamoya Disease in the United States. <i>Stroke</i> , 1998, 29, 1347-1351.	2.0	295
20	Agreement and Variability in the Interpretation of Early CT Changes in Stroke Patients Qualifying for Intravenous rtPA Therapy. <i>Stroke</i> , 1999, 30, 1528-1533.	2.0	285
21	Speed of Intracranial Clot Lysis With Intravenous Tissue Plasminogen Activator Therapy. <i>Circulation</i> , 2001, 103, 2897-2902.	1.6	274
22	Intravenous autologous bone marrow mononuclear cells for ischemic stroke. <i>Annals of Neurology</i> , 2011, 70, 59-69.	5.3	259
23	Timing of Recanalization After Tissue Plasminogen Activator Therapy Determined by Transcranial Doppler Correlates With Clinical Recovery From Ischemic Stroke. <i>Stroke</i> , 2000, 31, 1812-1816.	2.0	241
24	Improving Delivery of Acute Stroke Therapy. <i>Stroke</i> , 2002, 33, 160-166.	2.0	232
25	Streamlining of prehospital stroke management: the golden hour. <i>Lancet Neurology</i> , The, 2013, 12, 585-596.	10.2	229
26	Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. <i>Lancet Neurology</i> , The, 2018, 17, 885-894.	10.2	229
27	A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolGardâ„¢ System and Icyâ„¢ catheter following cardiac arrest. <i>Resuscitation</i> , 2004, 62, 143-150.	3.0	228
28	Transcranial Doppler Ultrasound Criteria for Recanalization After Thrombolysis for Middle Cerebral Artery Stroke. <i>Stroke</i> , 2000, 31, 1128-1132.	2.0	226
29	Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke. <i>Stroke</i> , 2010, 41, 707-711.	2.0	226
30	15d-Prostaglandin J <sub>2</sub> Activates Peroxisome Proliferator-Activated Receptor-Î³, Promotes Expression of Catalase, and Reduces Inflammation, Behavioral Dysfunction, and Neuronal Loss after Intracerebral Hemorrhage in Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 811-820.	4.3	222
31	Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. <i>Annals of Neurology</i> , 2009, 66, 28-38.	5.3	220
32	Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke. <i>Archives of Neurology</i> , 2001, 58, 2009.	4.5	216
33	Increased Pelvic Vein Thrombi in Cryptogenic Stroke. <i>Stroke</i> , 2004, 35, 46-50.	2.0	215
34	Hypertension and Its Treatment in the NINDS rt-PA Stroke Trial. <i>Stroke</i> , 1998, 29, 1504-1509.	2.0	209
35	Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. <i>Journal of Neuroscience Research</i> , 2010, 88, 1569-1576.	2.9	209
36	Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO). <i>Stroke</i> , 2005, 36, 1512-1518.	2.0	203

#	ARTICLE	IF	CITATIONS
37	Transcription Factor Nrf2 Protects the Brain From Damage Produced by Intracerebral Hemorrhage. <i>Stroke</i> , 2007, 38, 3280-3286.	2.0	202
38	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. <i>Stroke</i> , 2016, 47, 2373-2379.	2.0	193
39	Acute Stroke Imaging Research Roadmap II. <i>Stroke</i> , 2013, 44, 2628-2639.	2.0	192
40	Autologous Bone Marrow Mononuclear Cells Enhance Recovery after Acute Ischemic Stroke in Young and Middle-Aged Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 140-149.	4.3	190
41	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. <i>Lancet Neurology</i> , The, 2016, 15, 925-933.	10.2	187
42	Yield of Transcranial Doppler in Acute Cerebral Ischemia. <i>Stroke</i> , 1999, 30, 1604-1609.	2.0	185
43	Cell death in experimental intracerebral hemorrhage: The "black hole" model of hemorrhagic damage. <i>Annals of Neurology</i> , 2002, 51, 517-524.	5.3	183
44	Clinical Deterioration Following Improvement in the NINDS rt-PA Stroke Trial. <i>Stroke</i> , 2001, 32, 661-668.	2.0	180
45	Acetaminophen for Altering Body Temperature in Acute Stroke. <i>Stroke</i> , 2002, 33, 130-135.	2.0	180
46	Accuracy and Criteria for Localizing Arterial Occlusion With Transcranial Doppler. <i>Journal of Neuroimaging</i> , 2000, 10, 1-12.	2.0	179
47	Does the National Institutes of Health Stroke Scale Favor Left Hemisphere Strokes?. <i>Stroke</i> , 1999, 30, 2355-2359.	2.0	173
48	Early Exclusive Use of the Affected Forelimb After Moderate Transient Focal Ischemia in Rats. <i>Stroke</i> , 2000, 31, 1144-1152.	2.0	172
49	Aggressive Mechanical Clot Disruption. <i>Stroke</i> , 2005, 36, 292-296.	2.0	172
50	Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic Stroke. <i>Stroke</i> , 1995, 26, 602-605.	2.0	172
51	Constraint-Induced Movement Therapy During Early Stroke Rehabilitation. <i>Neurorehabilitation and Neural Repair</i> , 2007, 21, 14-24.	2.9	167
52	Hypothermia for acute ischaemic stroke. <i>Lancet Neurology</i> , The, 2013, 12, 275-284.	10.2	167
53	Nuclear Factor- $\kappa$ B and Cell Death After Experimental Intracerebral Hemorrhage in Rats. <i>Stroke</i> , 1999, 30, 2472-2478.	2.0	166
54	Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges. <i>Lancet Neurology</i> , The, 2017, 16, 227-237.	10.2	164

#	ARTICLE	IF	CITATIONS
55	Safety and Tolerability of NXY-059 for Acute Intracerebral Hemorrhage. <i>Stroke</i> , 2007, 38, 2262-2269.	2.0	162
56	Specific Transcranial Doppler Flow Findings Related to the Presence and Site of Arterial Occlusion. <i>Stroke</i> , 2000, 31, 140-146.	2.0	159
57	A Pilot Randomized Clinical Safety Study of Sonothrombolysis Augmentation With Ultrasound-Activated Perflutren-Lipid Microspheres for Acute Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1464-1469.	2.0	158
58	Carotid Artery Disease Following External Cervical Irradiation. <i>Annals of Surgery</i> , 1981, 194, 609-615.	4.2	151
59	Intravenous Tissue Plasminogen Activator and Flow Improvement in Acute Ischemic Stroke Patients with Internal Carotid Artery Occlusion. <i>Journal of Neuroimaging</i> , 2002, 12, 119-123.	2.0	150
60	Neuronal PPAR $\gamma$ Deficiency Increases Susceptibility to Brain Damage after Cerebral Ischemia. <i>Journal of Neuroscience</i> , 2009, 29, 6186-6195.	3.6	148
61	Lubeluzole Treatment of Acute Ischemic Stroke. <i>Stroke</i> , 1997, 28, 2338-2346.	2.0	144
62	Thrombolytic Therapy for Patients Who Wake-Up With Stroke. <i>Stroke</i> , 2009, 40, 827-832.	2.0	139
63	Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale. <i>Stroke</i> , 2015, 46, 2238-2243.	2.0	139
64	Finding the Most Powerful Measures of the Effectiveness of Tissue Plasminogen Activator in the NINDS tPA Stroke Trial. <i>Stroke</i> , 2000, 31, 2335-2341.	2.0	138
65	Early Dramatic Recovery During Intravenous Tissue Plasminogen Activator Infusion. <i>Stroke</i> , 2002, 33, 1301-1307.	2.0	136
66	Neuroprotective Role of Haptoglobin after Intracerebral Hemorrhage. <i>Journal of Neuroscience</i> , 2009, 29, 15819-15827.	3.6	136
67	Yield and Accuracy of Urgent Combined Carotid/Transcranial Ultrasound Testing in Acute Cerebral Ischemia. <i>Stroke</i> , 2005, 36, 32-37.	2.0	135
68	Ischemia-Induced Translocation of Ca <sup>2+</sup> /Calmodulin-Dependent Protein Kinase II: Potential Role in Neuronal Damage. <i>Journal of Neurochemistry</i> , 1992, 58, 1743-1753.	3.9	134
69	Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). <i>Stroke</i> , 2016, 47, 2888-2895.	2.0	131
70	Activation of Emergency Medical Services for Acute Stroke in a Nonurban Population. <i>Stroke</i> , 2000, 31, 1925-1928.	2.0	129
71	<i>RNF213</i> Rare Variants in an Ethnically Diverse Population With Moyamoya Disease. <i>Stroke</i> , 2014, 45, 3200-3207.	2.0	129
72	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. <i>Circulation</i> , 2017, 135, 128-139.	1.6	129

#	ARTICLE	IF	CITATIONS
73	Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. <i>New England Journal of Medicine</i> , 2021, 385, 971-981.	27.0	128
74	IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. <i>Brain Research</i> , 2011, 1373, 189-194.	2.2	127
75	Ultrasound-Enhanced Thrombolysis for Acute Ischemic Stroke: Phase I. Findings of the CLOTBUST Trial. <i>Journal of Neuroimaging</i> , 2004, 14, 113-117.	2.0	125
76	Deterioration Following Spontaneous Improvement. <i>Stroke</i> , 2000, 31, 915-919.	2.0	121
77	Ischemic Stunning of the Brain. <i>Stroke</i> , 2004, 35, 449-452.	2.0	121
78	Stroke Treatment Academic Industry Roundtable X. <i>Stroke</i> , 2019, 50, 1026-1031.	2.0	120
79	NIHSS Training and Certification Using a New Digital Video Disk Is Reliable. <i>Stroke</i> , 2005, 36, 2446-2449.	2.0	118
80	Identifying Patients at High Risk for Poor Outcome After Intra-Arterial Therapy for Acute Ischemic Stroke. <i>Stroke</i> , 2009, 40, 1780-1785.	2.0	118
81	The IVH Score: A novel tool for estimating intraventricular hemorrhage volume: Clinical and research implications*. <i>Critical Care Medicine</i> , 2009, 37, 969-e1.	0.9	118
82	Outcomes of Endovascular Thrombectomy vs Medical Management Alone in Patients With Large Ischemic Cores. <i>JAMA Neurology</i> , 2019, 76, 1147.	9.0	118
83	Headache in the Emergency Department. <i>Headache</i> , 2001, 41, 537-541.	3.9	116
84	AXIS. <i>Stroke</i> , 2010, 41, 2545-2551.	2.0	116
85	Stroke Neurologist's Perspective on the New Endovascular Trials. <i>Stroke</i> , 2015, 46, 1447-1452.	2.0	116
86	tPA-Associated Reperfusion After Acute Stroke Demonstrated by SPECT. <i>Stroke</i> , 1998, 29, 429-432.	2.0	113
87	Is the Benefit of Early Recanalization Sustained at 3 Months?. <i>Stroke</i> , 2003, 34, 695-698.	2.0	113
88	Distinct patterns of intracerebral hemorrhage-induced alterations in NF- $\kappa$ B subunit, iNOS, and COX-2 expression. <i>Journal of Neurochemistry</i> , 2006, 101, 652-663.	3.9	113
89	Zero on the NIHSS Does Not Equal the Absence of Stroke. <i>Annals of Emergency Medicine</i> , 2011, 57, 42-45.	0.6	111
90	Sustained Benefit of a Community and Professional Intervention to Increase Acute Stroke Therapy. <i>Archives of Internal Medicine</i> , 2003, 163, 2198.	3.8	110

#	ARTICLE	IF	CITATIONS
91	Clinical trials for cytoprotection in stroke. <i>NeuroRx</i> , 2004, 1, 46-70.	6.0	110
92	Current Medical and Surgical Therapy for Cerebrovascular Disease. <i>New England Journal of Medicine</i> , 1987, 317, 1505-1516.	27.0	108
93	Emergence of the Primary Pediatric Stroke Center. <i>Stroke</i> , 2014, 45, 2018-2023.	2.0	108
94	Ethanol Plus Caffeine (Caffeinol) for Treatment of Ischemic Stroke. <i>Stroke</i> , 2003, 34, 1246-1251.	2.0	106
95	Benefits of Stroke Treatment Using a Mobile Stroke Unit Compared With Standard Management. <i>Stroke</i> , 2015, 46, 3370-3374.	2.0	106
96	Neuroprotective Therapy. <i>Seminars in Neurology</i> , 1998, 18, 485-492.	1.4	105
97	Constraint-Induced Movement Therapy. <i>Stroke</i> , 2004, 35, 2699-2701.	2.0	105
98	Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window. <i>Stroke</i> , 2009, 40, 2433-2437.	2.0	105
99	Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs. <i>Stroke</i> , 2002, 33, 306-307.	2.0	103
100	Is Intra-Arterial Thrombolysis Safe After Full-Dose Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke?. <i>Stroke</i> , 2007, 38, 80-84.	2.0	103
101	Intracerebral Hemorrhage in Cocaine Users. <i>Stroke</i> , 2010, 41, 680-684.	2.0	103
102	Thrombolysis in Stroke Despite Contraindications or Warnings?. <i>Stroke</i> , 2013, 44, 727-733.	2.0	102
103	A Randomized, Controlled Trial to Teach Middle School Children to Recognize Stroke and Call 911. <i>Stroke</i> , 2007, 38, 2972-2978.	2.0	101
104	The Virtual International Stroke Trials Archive. <i>Stroke</i> , 2007, 38, 1905-1910.	2.0	101
105	Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?. <i>Stroke</i> , 2018, 49, 2398-2405.	2.0	100
106	Ischemia-Induced Neuronal Damage: A Role for Calcium/Calmodulin-Dependent Protein Kinase II. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1996, 16, 1-6.	4.3	97
107	Establishing the First Mobile Stroke Unit in the United States. <i>Stroke</i> , 2015, 46, 1384-1391.	2.0	97
108	Can Comprehensive Stroke Centers Erase the "Weekend Effect"? <i>Cerebrovascular Diseases</i> , 2009, 27, 107-113.	1.7	96

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2015, 14, 575-584.	10.2	95
110	Established treatments for acute ischaemic stroke. <i>Lancet</i> , The, 2007, 369, 319-330.	13.7	94
111	An Alternative Method for the Quantitation of Neuronal Damage after Experimental Middle Cerebral Artery Occlusion in Rats: Analysis of Behavioral Deficit. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1996, 16, 705-713.	4.3	93
112	The Argatroban and Tissue-Type Plasminogen Activator Stroke Study. <i>Stroke</i> , 2012, 43, 770-775.	2.0	93
113	Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. <i>Journal of Neuroscience Research</i> , 2011, 89, 833-839.	2.9	90
114	CLOTBUST: Design of a Randomized Trial of Ultrasound-Enhanced Thrombolysis for Acute Ischemic Stroke. <i>Journal of Neuroimaging</i> , 2004, 14, 108-112.	2.0	89
115	Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. <i>Stroke</i> , 2016, 47, 1389-1398.	2.0	88
116	Racial and Gender Differences in Stroke Severity, Outcomes, and Treatment in Patients with Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e255-e261.	1.6	87
117	Systemic Thrombolysis in Patients With Acute Ischemic Stroke and Internal Carotid Artery Occlusion. <i>Stroke</i> , 2012, 43, 125-130.	2.0	86
118	Optimizing Prediction Scores for Poor Outcome After Intra-Arterial Therapy in Anterior Circulation Acute Ischemic Stroke. <i>Stroke</i> , 2013, 44, 3324-3330.	2.0	86
119	The Spot Sign in Intracerebral Hemorrhage: The Importance of Looking for Contrast Extravasation. <i>Cerebrovascular Diseases</i> , 2010, 29, 217-220.	1.7	85
120	Carotid Stenosis. <i>New England Journal of Medicine</i> , 2013, 369, 1143-1150.	27.0	82
121	Posterior Circulation Stroke is Associated with Prolonged Door-to-Needle Time. <i>International Journal of Stroke</i> , 2015, 10, 672-678.	5.9	81
122	Should Mild or Moderate Stroke Patients Be Admitted to an Intensive Care Unit?. <i>Stroke</i> , 2001, 32, 871-876.	2.0	80
123	Peroxisome-proliferator-activated receptor-gamma (PPAR $\gamma$ ) activation protects neurons from NMDA excitotoxicity. <i>Brain Research</i> , 2006, 1073-1074, 460-469.	2.2	80
124	Real-World Treatment Trends in Endovascular Stroke Therapy. <i>Stroke</i> , 2019, 50, 683-689.	2.0	80
125	Thrombus Burden Is Associated With Clinical Outcome After Intra-Arterial Therapy for Acute Ischemic Stroke. <i>Stroke</i> , 2008, 39, 3231-3235.	2.0	79
126	Thrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity. <i>Stroke</i> , 2010, 41, 2612-2617.	2.0	79



#	ARTICLE	IF	CITATIONS
127	A Broad Diagnostic Battery for Bedside Transcranial Doppler to Detect Flow Changes With Internal Carotid Artery Stenosis or Occlusion. <i>Journal of Neuroimaging</i> , 2001, 11, 236-242.	2.0	77
128	Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPAR $\gamma$ ) and 15d-prostaglandin J $_2$ -Mediated protection of brain after experimental cerebral ischemia in rat. <i>Brain Research</i> , 2006, 1096, 196-203.	2.2	74
129	Increased Blood-Brain Barrier Permeability on Perfusion CT Might Predict Malignant Middle Cerebral Artery Infarction. <i>Stroke</i> , 2010, 41, 2539-2544.	2.0	74
130	Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes: Consensus Recommendations From Stroke Therapy Academic Industry Roundtable XI. <i>Stroke</i> , 2021, 52, 3054-3062.	2.0	74
131	Pretreatment Blood-Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. <i>Stroke</i> , 2014, 45, 2030-2035.	2.0	73
132	Argatroban tPA Stroke Study. <i>Archives of Neurology</i> , 2006, 63, 1057.	4.5	72
133	Combined Neuroprotective Modalities Coupled with Thrombolysis in Acute Ischemic Stroke: A Pilot Study of Caffeinol and Mild Hypothermia. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 86-96.	1.6	72
134	Changes in Spleen Size in Patients with Acute Ischemic Stroke: A Pilot Observational Study. <i>International Journal of Stroke</i> , 2013, 8, 60-67.	5.9	72
135	Machine Learning-Enabled Automated Determination of Acute Ischemic Core From Computed Tomography Angiography. <i>Stroke</i> , 2019, 50, 3093-3100.	2.0	71
136	Endovascular Therapeutic Hypothermia for Acute Ischemic Stroke: ICTuS 2/3 Protocol. <i>International Journal of Stroke</i> , 2014, 9, 117-125.	5.9	70
137	Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.0	69
138	Combination Therapy Stroke Trial: Recombinant Tissue-Type Plasminogen Activator with/without Lubeluzole. <i>Cerebrovascular Diseases</i> , 2001, 12, 258-263.	1.7	66
139	Design of a Prospective, Dose-Escalation Study Evaluating the Safety of Pioglitazone for Hematoma Resolution in Intracerebral Hemorrhage (SHRINC). <i>International Journal of Stroke</i> , 2013, 8, 388-396.	5.9	65
140	Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria. <i>Stroke</i> , 2013, 44, 2500-2505.	2.0	65
141	Pilot Dose-Escalation Study of Caffeine Plus Ethanol (Caffeinol) in Acute Ischemic Stroke. <i>Stroke</i> , 2003, 34, 1242-1245.	2.0	64
142	Functional Reorganization and Recovery After Constraint-Induced Movement Therapy in Subacute Stroke: Case Reports. <i>Neurocase</i> , 2006, 12, 50-60.	0.6	64
143	Prehospital Utility of Rapid Stroke Evaluation Using In-Ambulance Telemedicine. <i>Stroke</i> , 2014, 45, 2342-2347.	2.0	64
144	Citicoline for treatment of experimental focal ischemia: Histologic and behavioral outcome. <i>Neurological Research</i> , 1996, 18, 570-574.	1.3	63

#	ARTICLE	IF	CITATIONS
145	Telemedicine Can Replace the Neurologist on a Mobile Stroke Unit. <i>Stroke</i> , 2017, 48, 493-496.	2.0	63
146	The Current Status of Neuronal Protective Therapy: Why Have All Neuronal Protective Drugs Worked in Animals but None So Far in Stroke Patients?. <i>Cerebrovascular Diseases</i> , 1994, 4, 115-120.	1.7	61
147	Small vessel disease and clinical outcomes after IV rt-PA treatment. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 72-77.	2.1	61
148	Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 338-347.	10.2	61
149	Implementing a Mobile Stroke Unit Program in the United States. <i>JAMA Neurology</i> , 2015, 72, 229.	9.0	60
150	Grading Carotid Stenosis With Ultrasound. <i>Stroke</i> , 1997, 28, 1208-1210.	2.0	60
151	Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. <i>Journal of Neuroscience Research</i> , 2010, 88, 2869-2876.	2.9	59
152	Intravenous TPA for Very Old Stroke Patients. <i>European Neurology</i> , 2005, 54, 140-144.	1.4	58
153	Anticoagulation After Cardioembolic Stroke. <i>Archives of Neurology</i> , 2008, 65, 1169.	4.5	58
154	Thrombelastography Detects Possible Coagulation Disturbance in Patients With Intracerebral Hemorrhage With Hematoma Enlargement. <i>Stroke</i> , 2014, 45, 683-688.	2.0	58
155	Treatment of Acute Intracerebral Hemorrhage with Îµ-Aminocaproic Acid: A Pilot Study. <i>Neurocritical Care</i> , 2004, 1, 47-52.	2.4	57
156	Endovascular Thrombectomy for Acute Ischemic Strokes. <i>Stroke</i> , 2020, 51, 1207-1217.	2.0	55
157	Ultrasound-Enhanced Thrombolysis for Acute Ischemic Stroke: Phase I. Findings of the CLOTBUST Trial. , 2004, 14, 113-117.		55
158	Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. <i>Annals of Neurology</i> , 2001, 49, 736-744.	5.3	54
159	The PRE-hospital Stroke Treatment Organization. <i>International Journal of Stroke</i> , 2017, 12, 932-940.	5.9	54
160	Immunohistochemical Determination of Calciumâ€™Calmodulin Binding Predicts Neuronal Damage after Global Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1989, 9, 805-811.	4.3	52
161	Therapeutic Time Window and Dose Dependence of Xenon Delivered via Echogenic Liposomes for Neuroprotection in Stroke. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 773-784.	3.9	52
162	Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection. <i>Annals of Neurology</i> , 2020, 87, 419-433.	5.3	52

#	ARTICLE	IF	CITATIONS
163	Acute Stroke Therapy at the Millennium: Consummating the Marriage Between the Laboratory and Bedside. <i>Stroke</i> , 1999, 30, 1722-1728.	2.0	51
164	Additional Outcomes and Subgroup Analyses of NXY-059 for Acute Ischemic Stroke in the SAINT I Trial. <i>Stroke</i> , 2006, 37, 2970-2978.	2.0	51
165	Interplay Between the Gamma Isoform of PKC and Calcineurin in Regulation of Vulnerability to Focal Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 343-349.	4.3	50
166	Benefits of stroke treatment delivered using a mobile stroke unit trial. <i>International Journal of Stroke</i> , 2018, 13, 321-327.	5.9	50
167	Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes. <i>Stroke</i> , 2021, 52, 57-69.	2.0	49
168	New Uses for Calcium Channel Blockers. <i>Drugs</i> , 1993, 46, 961-975.	10.9	48
169	Thromboelastography in Patients with Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2015, 10, 194-201.	5.9	48
170	Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke. <i>Stroke</i> , 2016, 47, 2880-2887.	2.0	48
171	Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke. <i>Stroke</i> , 1997, 28, 1830-1834.	2.0	48
172	Neurofilament Proteolysis after Focal Ischemia; When Do Cells Die after Experimental Stroke?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 652-660.	4.3	47
173	Prehospital stroke management in the thrombectomy era. <i>Lancet Neurology</i> , The, 2020, 19, 601-610.	10.2	47
174	Demonstration of hypoperfusion surrounding intracerebral hematoma in humans. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 1996, 6, 17-24.	1.6	46
175	The Impact of Imbalances in Baseline Stroke Severity on Outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. <i>Annals of Emergency Medicine</i> , 2005, 45, 377-384.	0.6	46
176	Aggressive Blood Pressure“Lowering Treatment Before Intravenous Tissue Plasminogen Activator Therapy in Acute Ischemic Stroke. <i>Archives of Neurology</i> , 2008, 65, 1174-8.	4.5	46
177	Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. <i>Stroke</i> , 2004, 35, 113-7.		46
178	LOAD: A Pilot Study of the Safety of Loading of Aspirin and Clopidogrel in Acute Ischemic Stroke and Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2008, 17, 26-29.	1.6	44
179	Neuroprotection and the Ischemic Cascade. <i>CNS Spectrums</i> , 2000, 5, 52-58.	1.2	43
180	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. <i>Journal of Neurology</i> , 2015, 262, 459-468.	3.6	43

#	ARTICLE	IF	CITATIONS
181	Latest advances in intracerebral hemorrhage. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 17-22.	4.2	42
182	Is the Drip-and-Ship Approach to Delivering Thrombolysis for Acute Ischemic Stroke Safe?. <i>Journal of Emergency Medicine</i> , 2011, 41, 135-141.	0.7	42
183	CLOTBUST-Hands Free. <i>Stroke</i> , 2013, 44, 3376-3381.	2.0	41
184	Mobile Stroke Unit Computed Tomography Angiography Substantially Shortens Door-to-Puncture Time. <i>Stroke</i> , 2020, 51, 1613-1615.	2.0	40
185	The effects of telemedicine on racial and ethnic disparities in access to acute stroke care. <i>Journal of Telemedicine and Telecare</i> , 2016, 22, 114-120.	2.7	39
186	Utilization and Availability of Advanced Imaging in Patients With Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006989.	2.2	39
187	Stroke Outcome in Clinical Trial Patients Deriving From Different Countries. <i>Stroke</i> , 2009, 40, 35-40.	2.0	37
188	Brain extraction of a calcium channel blocker. <i>Annals of Neurology</i> , 1987, 21, 171-175.	5.3	36
189	Accuracy of Serial National Institutes of Health Stroke Scale Scores to Identify Artery Status in Acute Ischemic Stroke. <i>Circulation</i> , 2007, 115, 2660-2665.	1.6	36
190	Pharmacological Deep Vein Thrombosis Prophylaxis Does Not Lead to Hematoma Expansion in Intracerebral Hemorrhage With Intraventricular Extension. <i>Stroke</i> , 2011, 42, 705-709.	2.0	36
191	Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy. <i>Stroke</i> , 2011, 42, 1046-1050.	2.0	36
192	Validity of Acute Stroke Lesion Volume Estimation by Diffusion-Weighted Imaging—Alberta Stroke Program Early Computed Tomographic Score Depends on Lesion Location in 496 Patients With Middle Cerebral Artery Stroke. <i>Stroke</i> , 2014, 45, 3583-3588.	2.0	36
193	Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke. <i>Annals of Neurology</i> , 2016, 80, 211-218.	5.3	36
194	Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage. <i>Scientific Reports</i> , 2018, 8, 450.	3.3	36
195	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , 2018, 13, 175-189.	5.9	36
196	Paramedic and Emergency Department Care of Stroke: Baseline Data From a Citywide Performance Improvement Study. <i>American Journal of Critical Care</i> , 2003, 12, 411-417.	1.6	36
197	Safety and tolerability of arundic acid in acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2006, 251, 50-56.	0.6	35
198	Stroke Program Review Group. <i>Stroke</i> , 2008, 39, 1364-1370.	2.0	35

#	ARTICLE	IF	CITATIONS
199	Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. <i>Stem Cells</i> , 2019, 37, 1481-1491.	3.2	35
200	Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. <i>Journal of Neuroscience Methods</i> , 2005, 143, 209-216.	2.5	34
201	Using Telemedicine to Facilitate Thrombolytic Therapy for Patients with Acute Stroke. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2006, 32, 199-205.	0.7	34
202	Inflammatory response to intraventricular hemorrhage: Time course, magnitude and effect of t-PA. <i>Journal of the Neurological Sciences</i> , 2012, 315, 93-95.	0.6	34
203	Decompressive hemicraniectomy with or without clot evacuation for large spontaneous supratentorial intracerebral hemorrhages. <i>Clinical Neurology and Neurosurgery</i> , 2015, 128, 117-122.	1.4	34
204	The Story of Intracerebral Hemorrhage. <i>Stroke</i> , 2021, 52, 1905-1914.	2.0	34
205	Combining Insulin-Like Growth Factor Derivatives Plus Caffeinol Produces Robust Neuroprotection After Stroke in Rats. <i>Stroke</i> , 2005, 36, 129-134.	2.0	33
206	Neurofluctuation in patients with subcortical ischemic stroke. <i>Neurology</i> , 2014, 83, 398-405.	1.1	33
207	A randomized controlled trial to optimize patient's selection for endovascular treatment in acute ischemic stroke (SELECT2): Study protocol. <i>International Journal of Stroke</i> , 2022, 17, 689-693.	5.9	33
208	Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy. <i>JAMA Neurology</i> , 2021, 78, 916.	9.0	33
209	Subjective Experiences of 24 Patients Dramatically Recovering From Stroke. <i>Stroke</i> , 1995, 26, 1285-1288.	2.0	33
210	Endovascular recanalization of internal carotid artery occlusion in acute ischemic stroke. <i>American Journal of Neuroradiology</i> , 2005, 26, 2591-4.	2.4	33
211	Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management. <i>JAMA Neurology</i> , 2022, 79, 281.	9.0	33
212	Intravenous Tissue Plasminogen Activator in Patients With Cocaine-Associated Acute Ischemic Stroke. <i>Stroke</i> , 2009, 40, 3635-3637.	2.0	32
213	Elective Stenting of Extracranial Carotid Arteries. <i>Circulation</i> , 1997, 95, 303-305.	1.6	32
214	Neuronal Protection and Preservation of Calcium/Calmodulin-Dependent Protein Kinase II and Protein Kinase C Activity by Dextrorphan Treatment in Global Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 550-557.	4.3	31
215	Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo. <i>Stroke</i> , 2020, 51, 1226-1230.	2.0	31
216	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. <i>Stroke</i> , 2015, 46, 395-400.	2.0	30

#	ARTICLE	IF	CITATIONS
217	Clinical Aspects of the Use of Calcium Antagonists in Cerebrovascular Disease. <i>Clinical Neuropharmacology</i> , 1991, 14, 373-390.	0.7	29
218	Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women. <i>Stroke</i> , 2002, 33, 2506-2508.	2.0	29
219	CLOTBUST-Hands Free. <i>Stroke</i> , 2013, 44, 1641-1646.	2.0	29
220	tPA for Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1615.	7.4	29
221	Impact of mobile stroke units. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 815-822.	1.9	29
222	Thrombelastography Detects the Anticoagulant Effect of Rivaroxaban in Patients With Stroke. <i>Stroke</i> , 2014, 45, 880-883.	2.0	28
223	Unique Contribution of Haptoglobin and Haptoglobin Genotype in Aneurysmal Subarachnoid Hemorrhage. <i>Frontiers in Physiology</i> , 2018, 9, 592.	2.8	28
224	Impact of Initial Imaging Protocol on Likelihood of Endovascular Stroke Therapy. <i>Stroke</i> , 2020, 51, 3055-3063.	2.0	28
225	Neuroprotection is unlikely to be effective in humans using current trial designs. <i>Stroke</i> , 2002, 33, 306-7.	2.0	28
226	Determinants of Effective Cooling During Endovascular Hypothermia. <i>Neurocritical Care</i> , 2012, 16, 413-420.	2.4	27
227	Stroke in the elderly. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 393-418.	1.8	27
228	Ca <sup>2+</sup> /calmodulin-dependent protein kinase II in postsynaptic densities after reversible cerebral ischemia in rats. <i>Brain Research</i> , 1996, 709, 103-110.	2.2	26
229	Quantification of Cerebral Edema After Subarachnoid Hemorrhage. <i>Neurocritical Care</i> , 2016, 25, 64-70.	2.4	26
230	Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 505-510.	2.1	26
231	STAIR X. <i>Stroke</i> , 2018, 49, 2241-2247.	2.0	26
232	African Americans and Women Have the Highest Stroke Mortality in Texas. <i>Stroke</i> , 1997, 28, 15-18.	2.0	26
233	Emergency Identification and Treatment of Acute Ischemic Stroke. <i>Annals of Emergency Medicine</i> , 1997, 30, 642-653.	0.6	25
234	Telemedicine-Guided Carotid and Transcranial Ultrasound. <i>Stroke</i> , 2006, 37, 229-230.	2.0	25

#	ARTICLE	IF	CITATIONS
235	Rethinking Training and Distribution of Vascular Neurology Interventionists in the Era of Thrombectomy. <i>Stroke</i> , 2017, 48, 2313-2317.	2.0	25
236	Safety and efficacy of dual antiplatelet pretreatment in patients with ischemic stroke treated with IV thrombolysis. <i>Neurology</i> , 2020, 94, e657-e666.	1.1	25
237	Mobile Stroke Units: Evidence, Gaps, and Next Steps. <i>Stroke</i> , 2022, 53, 2103-2113.	2.0	25
238	Oculomasticatory myorhythmia. <i>Annals of Neurology</i> , 1987, 22, 395-396.	5.3	24
239	Emergency Department Door-to-Puncture Time Since 2014. <i>Stroke</i> , 2019, 50, 1774-1780.	2.0	24
240	The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods. <i>International Journal of Stroke</i> , 2021, 16, 873-880.	5.9	24
241	Paradoxical Emboli from Calf and Pelvic Veins in Cryptogenic Stroke. <i>Journal of Neuroimaging</i> , 2003, 13, 218-223.	2.0	23
242	Impact of heart rate on admission on mortality and morbidity in acute ischaemic stroke patients – results from VISTA. <i>European Journal of Neurology</i> , 2016, 23, 1750-1756.	3.3	23
243	Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit. <i>Stroke</i> , 2018, 49, 1528-1530.	2.0	23
244	Use of a Smartphone-Based Mobile App for Weight Management in Obese Minority Stroke Survivors: Pilot Randomized Controlled Trial With Open Blinded End Point. <i>JMIR MHealth and UHealth</i> , 2020, 8, e17816.	3.7	23
245	Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Stroke</i> , 2022, 53, 1993-2005.	2.0	23
246	Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2005, 14, 50-54.	1.6	22
247	Intracranial Atherosclerosis Is Associated with Progression of Neurological Deficit in Subcortical Stroke. <i>Cerebrovascular Diseases</i> , 2012, 33, 64-68.	1.7	22
248	The University of Texas Houston Stroke Registry (UTHSR): implementation of enhanced data quality assurance procedures improves data quality. <i>BMC Neurology</i> , 2013, 13, 61.	1.8	22
249	Details of a Prospective Protocol for a Collaborative Meta-Analysis of Individual Participant Data from all Randomized Trials of Intravenous rt-PA vs. Control: Statistical Analysis Plan for the Stroke Thrombolysis Trialists' Collaborative Meta-Analysis. <i>International Journal of Stroke</i> , 2013, 8, 278-283.	5.9	22
250	Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 3647-3651.	1.6	22
251	CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. <i>Stroke</i> , 2004, 35, 108-112.		22
252	Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 1998, 7, 421-425.	1.6	21



#	ARTICLE	IF	CITATIONS
253	Recovery after Ischemic Stroke: Criteria for Good Outcome by Level of Disability at Day 7. <i>Cerebrovascular Diseases</i> , 2009, 28, 341-348.	1.7	21
254	Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. <i>BMJ: British Medical Journal</i> , 2019, 364, l895.	2.3	21
255	Triage imaging and outcome measures for large core stroke thrombectomy – a systematic review and meta-analysis. <i>Journal of NeuroInterventional Surgery</i> , 2020, 12, neurintsurg-2019-015509.	3.3	21
256	Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. <i>International Journal of Stroke</i> , 2022, 17, 806-809.	5.9	21
257	Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. <i>European Journal of Neurology</i> , 2015, 22, 163-169.	3.3	20
258	Endovascular thrombectomy in patients with large core ischemic stroke: a cost-effectiveness analysis from the SELECT study. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 875-882.	3.3	20
259	Cytoprotective Role of Haptoglobin in Brain After Experimental Intracerebral Hemorrhage. <i>Acta Neurochirurgica Supplementum</i> , 2011, 111, 107-112.	1.0	20
260	Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions. <i>American Journal of Neuroradiology</i> , 2002, 23, 1308-12.	2.4	20
261	Stroke Severity as Well as Time Should Determine Stroke Patient Triage. <i>Stroke</i> , 2013, 44, 555-557.	2.0	19
262	Swipe out Stroke: Feasibility and efficacy of using a smart-phone based mobile application to improve compliance with weight loss in obese minority stroke patients and their carers. <i>International Journal of Stroke</i> , 2016, 11, 593-603.	5.9	19
263	Telemedicine-guided education on secondary stroke and fall prevention following inpatient rehabilitation for Texas patients with stroke and their caregivers: a feasibility pilot study. <i>BMJ Open</i> , 2017, 7, e017340.	1.9	19
264	Antiplatelet Therapy after Ischemic Stroke or TIA. <i>New England Journal of Medicine</i> , 2018, 379, 291-292.	27.0	19
265	Dual Antiplatelet Therapy Is Associated With Coagulopathy Detectable by Thrombelastography in Acute Stroke. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 68-73.	2.8	19
266	Intravenous rt-PA: a tenth anniversary reflection. <i>World Neurosurgery</i> , 2007, 68, S12-S16.	1.3	18
267	Safety of Eptifibatide for Subcortical Stroke Progression. <i>Cerebrovascular Diseases</i> , 2009, 28, 595-600.	1.7	18
268	Thrombolysis With Intravenous Tissue Plasminogen Activator Predicts a Favorable Discharge Disposition in Patients With Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 700-704.	2.0	18
269	The Interaction of Aspiration Pneumonia with Demographic and Cerebrovascular Disease Risk Factors is Predictive of Discharge Level of Care in the Acute Stroke Patient. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2012, 91, 141-147.	1.4	18
270	HeadPoST. <i>Neurology</i> , 2018, 90, 885-889.	1.1	18



#	ARTICLE	IF	CITATIONS
271	Kids Identifying and Defeating Stroke (KIDS): Development and Implementation of a Multiethnic Health Education Intervention to Increase Stroke Awareness Among Middle School Students and Their Parents. <i>Health Promotion Practice</i> , 2010, 11, 95-103.	1.6	17
272	Selecting stroke patients for intra-arterial therapy. <i>Neurology</i> , 2012, 78, 755-761.	1.1	17
273	Is the ICH score a valid predictor of mortality in intracerebral hemorrhage?. <i>Journal of the American Association of Nurse Practitioners</i> , 2015, 27, 351-355.	0.9	17
274	SELECTION criteria for large core trials: dogma or data?. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 500-504.	3.3	17
275	Agreement Among Stroke Faculty and Fellows in Treating Ischemic Stroke Patients With Tissue-Type Plasminogen Activator and Thrombectomy. <i>Stroke</i> , 2017, 48, 222-224.	2.0	16
276	Machine Learning Automated Detection of Large Vessel Occlusion From Mobile Stroke Unit Computed Tomography Angiography. <i>Stroke</i> , 2022, 53, 1651-1656.	2.0	16
277	Wheel-Running Modestly Promotes Functional Recovery after a Unilateral Cortical Lesion in Rats. <i>Behavioural Neurology</i> , 2005, 16, 41-49.	2.1	15
278	Feasibility of carotid artery stenting in patients with angiographic string sign. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 1104-1109.	1.7	15
279	Caffeinol at the Receptor Level. <i>Stroke</i> , 2010, 41, 363-367.	2.0	15
280	Hospital-Acquired Symptomatic Urinary Tract Infection in Patients Admitted to an Academic Stroke Center Affects Discharge Disposition. <i>PM and R</i> , 2013, 5, 9-15.	1.6	15
281	Intravenous Fibrinolysis Eligibility: A Survey of Stroke Clinicians' Practice Patterns and Review of the Literature. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2130-2138.	1.6	15
282	Cerebral Venous Thrombosis "A New Diagnosis in Travel Medicine. <i>Journal of Travel Medicine</i> , 1996, 3, 137-137.	3.0	14
283	Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. <i>Neurocritical Care</i> , 2007, 6, 181-185.	2.4	14
284	Timing of thrombolysis for acute ischemic stroke: "timing is everything" or "everyone is different". <i>Annals of the New York Academy of Sciences</i> , 2012, 1268, 141-144.	3.8	14
285	Telemedicine-guided remote enrollment of patients into an acute stroke trial. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 38-42.	3.7	14
286	Thrombelastography Suggests Hypercoagulability in Patients with Renal Dysfunction and Intracerebral Hemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1350-1356.	1.6	14
287	Risk of intracranial hemorrhage associated with pregnancy in women with cerebral arteriovenous malformations. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 707-710.	3.3	14
288	Early Lessons From World War COVID Reinventing Our Stroke Systems of Care. <i>Stroke</i> , 2020, 51, 2268-2272.	2.0	14

#	ARTICLE	IF	CITATIONS
289	Intravenous TPA for Ischemic Stroke Patients: Houston Experience 1996–2000. <i>Stroke</i> , 2001, 32, 323-323.	2.0	14
290	Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort. <i>Annals of Neurology</i> , 2022, 92, 364-378.	5.3	14
291	Rodent Models of Stroke Limitations. <i>Archives of Neurology</i> , 1996, 53, 1067.	4.5	13
292	Safety and Feasibility of a Lower Dose Intravenous TPA Therapy for Ischemic Stroke beyond the First Three Hours. <i>Cerebrovascular Diseases</i> , 2005, 19, 260-266.	1.7	13
293	The NINDS Stroke Progress Review Group Final Analysis and Recommendations. <i>Stroke</i> , 2013, 44, 2343-2350.	2.0	13
294	Patient Refusal of Thrombolytic Therapy for Suspected Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2015, 10, 882-886.	5.9	13
295	National Institutes of Health StrokeNet During the Time of COVID-19 and Beyond. <i>Stroke</i> , 2020, 51, 2580-2586.	2.0	13
296	Fifty Years of Acute Ischemic Stroke Treatment: A Personal History. <i>Cerebrovascular Diseases</i> , 2021, 50, 666-680.	1.7	13
297	Paramedic and emergency department care of stroke: baseline data from a citywide performance improvement study. <i>American Journal of Critical Care</i> , 2003, 12, 411-7.	1.6	13
298	Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats. <i>Translational Stroke Research</i> , 2012, 3, 146-153.	4.2	12
299	Bringing Emergency Neurology to Ambulances: Mobile Stroke Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 713-717.	2.1	12
300	Retrospective collection of 90-day modified Rankin Scale is accurate. <i>Clinical Trials</i> , 2020, 17, 637-643.	1.6	12
301	Coagulation Differences Detectable in Deep and Lobar Primary Intracerebral Hemorrhage Using Thromboelastography. <i>Neurosurgery</i> , 2020, 87, 918-924.	1.1	12
302	Metastatic renal cell carcinoma simulating glomus jugulare tumor. <i>Journal of Surgical Oncology</i> , 1987, 35, 201-203.	1.7	11
303	ISCHEMIC STROKE. <i>Neurologic Clinics</i> , 1998, 16, 355-372.	1.8	11
304	Pattern of Response of National Institutes of Health Stroke Scale Components to Early Recanalization in the CLOTBUST Trial. <i>Stroke</i> , 2010, 41, 466-470.	2.0	11
305	Iodinated Contrast Does Not Alter Clotting Dynamics in Acute Ischemic Stroke as Measured by Thromboelastography. <i>Stroke</i> , 2014, 45, 462-466.	2.0	11
306	Radiation Monitoring Results from the First Year of Operation of a Unique Ambulance-based Computed Tomography Unit for the Improved Diagnosis and Treatment of Stroke Patients. <i>Health Physics</i> , 2016, 110, S73-S80.	0.5	11

#	ARTICLE	IF	CITATIONS
307	To Treat or Not to Treat?. Stroke, 2018, 49, 1933-1938.	2.0	11
308	National Institutes of Health Stroke Scale as an Outcome Measure for Acute Stroke Trials. Stroke, 2021, 52, 142-143.	2.0	11
309	Clinical and Neuroimaging Outcomes of Direct Thrombectomy vs Bridging Therapy in Large Vessel Occlusion. Neurology, 2021, 96, e2839-e2853.	1.1	11
310	Targeting Hemoglobin to Reduce Delayed Cerebral Ischemia After Subarachnoid Hemorrhage. Translational Stroke Research, 2022, 13, 725-735.	4.2	11
311	Hemorrhage Enlargement Is More Frequent in the First 2 Hours: A Prehospital Mobile Stroke Unit Study. Stroke, 2022, 53, 2352-2360.	2.0	11
312	Preventing Stroke. Circulation, 2001, 103, 2321-2322.	1.6	10
313	Does Clinical-CT "Mismatch" Predict Early Response to Treatment with Recombinant Tissue Plasminogen Activator?. Cerebrovascular Diseases, 2006, 22, 384-388.	1.7	10
314	Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke. American Journal of Neuroradiology, 2011, 32, 998-1001.	2.4	10
315	Stroke: new horizons in treatment. Lancet Neurology, The, 2014, 13, 2-3.	10.2	10
316	Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis. Journal of Hypertension, 2021, 39, 266-272.	0.5	10
317	The NINDS stroke study group response. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 121-124.	1.6	9
318	The Complications of Cardioembolic Stroke: Lessons from the VISTA Database. Cerebrovascular Diseases, 2008, 26, 38-40.	1.7	9
319	The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond 3 Hours Versus Within 3 Hours. Stroke, 2008, 39, 473-475.	2.0	9
320	No Consensus on Definition Criteria for Stroke Registry Common Data Elements. Cerebrovascular Diseases Extra, 2011, 1, 84-92.	1.5	9
321	Nitric Oxide Facilitates Delivery and Mediates Improved Outcome of Autologous Bone Marrow Mononuclear Cells in a Rodent Stroke Model. PLoS ONE, 2012, 7, e32793.	2.5	9
322	Interhospital Transfer of Stroke Patients for Endovascular Treatment. Circulation, 2019, 139, 1578-1580.	1.6	9
323	Sonothrombolysis in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: An Individual Patient Data Meta-Analysis. Stroke, 2021, 52, 3786-3795.	2.0	9
324	Enhanced dispatch and rendezvous doubles the catchment area and number of patients treated on a mobile stroke unit. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104894.	1.6	9

#	ARTICLE	IF	CITATIONS
325	Emerging Stroke Therapies. <i>Seminars in Neurology</i> , 1986, 6, 285-292.	1.4	8
326	Adding to the Effectiveness of Intravenous Tissue Plasminogen Activator for Treating Acute Stroke. <i>Circulation</i> , 2003, 107, 2769-2770.	1.6	8
327	Antiplatelet Therapy and the Risk of Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke. <i>Archives of Neurology</i> , 2008, 65, 575-6.	4.5	8
328	Stroke treatment and prevention. <i>Neurology</i> , 2010, 75, S16-21.	1.1	8
329	Carotid Stenosis. <i>New England Journal of Medicine</i> , 2013, 369, 2359-2361.	27.0	8
330	Selection for Delayed Intravenous Alteplase Treatment Based on a Prognostic Score. <i>International Journal of Stroke</i> , 2015, 10, 90-94.	5.9	8
331	Direct Assessment of Health Utilities Using the Standard Gamble Among Patients With Primary Intracerebral Hemorrhage. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005606.	2.2	8
332	Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis. <i>European Journal of Neurology</i> , 2020, 27, 2453-2462.	3.3	8
333	Improving Stroke Treatment and Outcomes With Mobile Stroke Units. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 441.	7.4	8
334	Education Research: Challenges Faced by Neurology Trainees in a Neuro-Intervention Career Track. <i>Neurology</i> , 2021, 96, e2028-e2032.	1.1	8
335	Acute Antithrombotic Treatment of Ischemic Stroke. <i>Current Vascular Pharmacology</i> , 2014, 12, 353-364.	1.7	8
336	Sjögren's syndrome and other rheumatic disorders presenting to a neurology service. <i>Journal of Autoimmunity</i> , 1989, 2, 477-483.	6.5	7
337	NIHSS/EIC Mismatch Explains the > 1/3 MCA Conundrum. <i>Stroke</i> , 2003, 34, e148-9; author reply e148-9.	2.0	7
338	Bone marrow-derived mononuclear cell populations in pediatric and adult patients. <i>Cytotherapy</i> , 2009, 11, 480-484.	0.7	7
339	Changing Demographics at a Comprehensive Stroke Center Amidst the Rise in Primary Stroke Centers. <i>Stroke</i> , 2013, 44, 1117-1123.	2.0	7
340	Influence of Racial Differences on Outcomes after Thrombolytic Therapy in Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2014, 9, 613-617.	5.9	7
341	Mobile Stroke Units: Current and Future Impact on Stroke Care. <i>Seminars in Neurology</i> , 2021, 41, 009-015.	1.4	7
342	Integrated Stroke System Model Expands Availability of Endovascular Therapy While Maintaining Quality Outcomes. <i>Stroke</i> , 2021, 52, 1022-1029.	2.0	7

#	ARTICLE	IF	CITATIONS
343	Mobile Stroke Units: Current Evidence and Impact. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 71-81.	4.2	7
344	Management of primary hypertensive hemorrhage of the brain. <i>Current Treatment Options in Neurology</i> , 2004, 6, 435-442.	1.8	6
345	Alteplase for acute ischemic stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 301-318.	1.5	6
346	Stroke Progress Review Group. <i>Stroke</i> , 2013, 44, S111-3.	2.0	6
347	The Effect of Telemedicine on Access to Acute Stroke Care in Texas: The Story of Age Inequalities. <i>Stroke Research and Treatment</i> , 2015, 2015, 1-6.	0.8	6
348	14th International Symposium on Thrombolysis, Thrombectomy and Acute Stroke Therapy: Proceedings and summary of discussions. <i>International Journal of Stroke</i> , 2019, 14, 439-441.	5.9	6
349	Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist. <i>Stroke</i> , 2020, 51, 663-665.	2.0	6
350	Retrospectively Collected EQ-5D-5L Data as Valid Proxies for Imputing Missing Information in Longitudinal Studies. <i>Value in Health</i> , 2021, 24, 1720-1727.	0.3	6
351	The NIHSS Score and its Components can Predict Cortical Stroke. , 2013, 2, 1026.		6
352	Clot Strength as Measured by Thrombelastography Correlates with Platelet Reactivity in Stroke Patients. <i>Annals of Clinical and Laboratory Science</i> , 2015, 45, 301-7.	0.2	6
353	Asymptomatic Carotid Bruit and Stenosis. <i>Seminars in Neurology</i> , 1986, 6, 262-266.	1.4	5
354	Ischemic stroke pathophysiology. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 1999, 8, 114-116.	1.6	5
355	New era for management of primary hypertensive intracerebral hemorrhage. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 29-35.	4.2	5
356	Defining Intravenous Recombinant Tissue Plasminogen Activator Failure. <i>Stroke</i> , 2013, 44, 819-821.	2.0	5
357	Comparison Between a Standardized Questionnaire and Expert Clinicians for Capacity Assessment in Stroke Clinical Trials. <i>Stroke</i> , 2014, 45, e229-32.	2.0	5
358	CTP infarct core may predict poor outcome in stroke patients treated with IV t-PA. <i>Journal of the Neurological Sciences</i> , 2014, 340, 165-169.	0.6	5
359	Methodological issues for designing and conducting a multicenter, international clinical trial in Acute Stroke: Experience from ARTSS-2 trial. <i>Contemporary Clinical Trials</i> , 2015, 44, 139-148.	1.8	5
360	Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 67.	4.2	5

#	ARTICLE	IF	CITATIONS
361	Longitudinal Neuroimaging Evaluation of the Corticospinal Tract in Patients with Stroke Treated with Autologous Bone Marrow Cells. <i>Stem Cells Translational Medicine</i> , 2021, 10, 943-955.	3.3	5
362	Association Between 2010 Medicare Reform and Inpatient Rehabilitation Access in People With Intracerebral Hemorrhage. <i>Journal of the American Heart Association</i> , 2021, 10, e020528.	3.7	5
363	Successful conduct of an acute stroke clinical trial during COVID. <i>PLoS ONE</i> , 2021, 16, e0243603.	2.5	5
364	Kids Identifying and Defeating Stroke (KIDS): design of a school-based intervention to improve stroke awareness. <i>Ethnicity and Disease</i> , 2007, 17, 320-6.	2.3	5
365	Neuroprotection after cardiac arrest. <i>Lancet Neurology</i> , The, 2002, 1, 146.	10.2	4
366	Characteristics of Acute Stroke Patients Readmitted to Inpatient Rehabilitation Facilities: A Cohort Study. <i>PM and R</i> , 2021, 13, 479-487.	1.6	4
367	Acute Intravenous Tissue Plasminogen Activator Therapy does not Impact Community Discharge after Inpatient Rehabilitation. <i>International Journal of Neurorehabilitation</i> , 2015, 2, .	0.1	4
368	What is the Role of Stroke Units in Overall Care?. <i>Disease Management and Health Outcomes</i> , 1999, 6, 193-202.	0.4	3
369	The Argatroban and tPA Stroke Study. , 0, , 35-48.		3
370	Is It Ethical to Have a Placebo Arm in Reperfusion Trials in the 3- to 6-Hour Time Window?. <i>Stroke</i> , 2009, 40, 1541-1542.	2.0	3
371	Does Study Enrollment Delay Treatment With Intravenous Thrombolytics for Acute Ischemic Stroke?. <i>Stroke</i> , 2009, 40, 663-663.	2.0	3
372	Response to Letters by Furlan, and Kohrmann and Schwab. <i>Stroke</i> , 2009, 40, .	2.0	3
373	Introduction. <i>Stroke</i> , 2010, 41, S91.	2.0	3
374	Seeking best medical treatment for hyperacute intracerebral hemorrhage. <i>Neurology</i> , 2015, 84, 444-445.	1.1	3
375	Association Between Intravenous Thrombolysis and Anaphylaxis Among Medicare Beneficiaries With Acute Ischemic Stroke. <i>Stroke</i> , 2019, 50, 3283-3285.	2.0	3
376	Lone Star Stroke Consortium. <i>Stroke</i> , 2020, 51, 3778-3786.	2.0	3
377	Evolving Role of Mobile Stroke Units Within the Prehospital Stroke Systems of Care. <i>Stroke</i> , 2020, 51, 1637-1638.	2.0	3
378	Complexities of Reperfusion Therapy in Patients With Ischemic Stroke Pretreated With Direct Oral Anticoagulants. <i>JAMA Neurology</i> , 2021, 78, 517.	9.0	3

#	ARTICLE	IF	CITATIONS
379	Pharmacologic Modification of Acute Cerebral Ischemia. , 2004, , 1025-1058.		3
380	Immediate Recanalization of Largeâ€Vessel Occlusions by Tissue Plasminogen Activator Occurs in 28% of Patients Treated in a Mobile Stroke Unit. , 2022, 2, .		3
381	How Frequent is the One-Hour tPA Infusion Interrupted or Delayed?. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106471.	1.6	3
382	Thromboelastography Indices for Predicting Outcomes After Aneurysmal Subarachnoid Hemorrhage: A Prospective Study. Stroke, 2022, 53, 101161STROKEAHA122039372.	2.0	3
383	SITS-MOST: old myths laid to rest. Lancet Neurology, The, 2007, 6, 292-293.	10.2	2
384	Higher prehospital blood pressure prolongs door to needle thrombolysis times: a target for quality improvement?. American Journal of Emergency Medicine, 2016, 34, 1268-1272.	1.6	2
385	â€Last known wellâ€™ alone should not determine triage for patients with stroke and symptoms of large vessel occlusion. Journal of NeuroInterventional Surgery, 2017, 9, 334-335.	3.3	2
386	Transatlantic Differences in Management of Carotid Stenosis: BRIDGing the Gap in StrokeE Management (BRIDGE) Project. Neurohospitalist, The, 2018, 8, 113-123.	0.8	2
387	Intraosseous Administration of Tissue Plasminogen Activator on a Mobile Stroke Unit. Prehospital Emergency Care, 2019, 23, 447-452.	1.8	2
388	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. Seminars in Neurology, 2021, 41, 365-387.	1.4	2
389	Sex Disparities in Access to Acute Stroke Care: Can Telemedicine Mitigate this Effect?. Journal of Health Disparities Research and Practice, 2016, 9, .	1.1	2
390	Cocaine Use is Associated with More Rapid Clot Formation and Weaker Clot Strength in Acute Stroke Patients. , 2019, 2, .		2
391	Neurology Trainee Attitudes Toward Neurointervention: Results From an International Survey. , 2022, 2, .		2
392	Chapter 13 Thrombolytic Therapies. Blue Books of Practical Neurology, 2004, 29, 267-281.	0.1	1
393	Intracerebral Hemorrhage: Effective Therapy at Last?. International Journal of Stroke, 2006, 1, 30-31.	5.9	1
394	The Argatroban and tPA Stroke Study. Progress in Neurotherapeutics and Neuropsychopharmacology, 2008, 3, .	0.0	1
395	Preface. Stroke, 2009, 40, S1-S1.	2.0	1
396	Comment on US Geographic Distribution of Recombinant Tissue Plasminogen Activator Use by Hospitals for Acute Ischemic Stroke. Stroke, 2010, 41, e189; author reply e190.	2.0	1



#	ARTICLE	IF	CITATIONS
397	Pharmacologic Modification of Acute Cerebral Ischemia. , 2011, , 1049-1083.		1
398	Adjunctive Medical Therapies for Acute Stroke Thrombolysis. Stroke, 2013, 44, 2377-2379.	2.0	1
399	Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998â€”2011. International Journal of Stroke, 2016, 11, 198-205.	5.9	1
400	Non-contrast head CT-based thrombolysis for wake-up/unknown onset stroke is safe: A single-center study and meta-analysis. International Journal of Stroke, 2021, , 174749302110063.	5.9	1
401	Hematoma Enlargement as a Target for Treating Intracerebral Hemorrhage. Neurology, 2021, 97, 355-356.	1.1	1
402	Leveraging Multimedia Patient Engagement to Address Minority Cerebrovascular Health Needs: Prospective Observational Study. Journal of Medical Internet Research, 2021, 23, e28748.	4.3	1
403	Abstract WMP87: Comparison of Patient-centered Quality of Life Utilities Using 3 Different Methods Across Modified Rankin Scale Scores - Experience From the ARTSS-2 Trial (Randomized, Multi-center) Tj ETQq1 1 0.784314 rgBT /Over 49, .	2.0	1
404	Aneurysmal subarachnoid haemorrhageâ€™ cerebral vasospasm and prophylactic ibuprofen: a randomised controlled pilot trial protocol. BMJ Open, 2022, 12, e058895.	1.9	1
405	Mobile Stroke Unit Operational Metrics: Institutional Experience, Systematic Review and Meta-Analysis. Frontiers in Neurology, 2022, 13, .	2.4	1
406	The Spot Sign and Intraventricular Hemorrhage are Associated with Baseline Coagulopathy and Outcome in Intracerebral Hemorrhage. Neurocritical Care, 0, , .	2.4	1
407	Discussion of mitchell JB, Ballard DJ, whisnant JP, et al. What role do neurologists play in determining the costs and outcome of stroke patients? stroke 1996;27:1937â€”1943. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 267-271.	1.6	0
408	Acute Posterior Multifocal Placoid Pigment Epitheliopathy After Cerebral Sinus Thrombosis. Neuro-Ophthalmology, 2007, 31, 117-120.	1.0	0
409	Introduction. Neurotherapeutics, 2011, 8, 317-318.	4.4	0
410	Frank Michio Yatsu, MD (1932â€”2012). Neurology, 2012, 78, 1907-1908.	1.1	0
411	Frank Michio Yatsu, MD. Stroke, 2012, 43, 1193-1194.	2.0	0
412	Reprint: Frank M. Yatsu, M.D.. International Journal of Stroke, 2012, 7, 369-370.	5.9	0
413	Pharmacologic Modification of Acute Cerebral Ischemia. , 2016, , 916-936.e5.		0
414	Response by Barreto and Grotta to Letter Regarding Article, â€œRandomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)â€• Stroke, 2017, 48, e259.	2.0	0



#	ARTICLE	IF	CITATIONS
415	Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series. Journal of Emergency Medicine, 2019, 57, e167-e173.	0.7	0
416	Intravenous Thrombolysis. , 2019, , 58-79.		0
417	Neurological Deterioration in Acute Ischemic Stroke. , 2019, , 101-118.		0
418	Organization of Stroke Care. , 2019, , 215-225.		0
419	Ischemic Stroke Etiology and Secondary Prevention. , 2019, , 119-152.		0
420	Stroke in Critically Ill Cancer Patients. , 2019, , 1-13.		0
421	Dosing Tissue Plasminogen Activator on a Mobile Stroke Unit: Comparison Between Estimated and Hospital-Measured Weights. Journal of Neuroscience Nursing, 2021, 53, 166-169.	1.1	0
422	Stroke Systems of Care and Impact on Acute Stroke Treatment. , 2022, , 725-734.e4.		0
423	Pharmacologic Modification of Acute Cerebral Ischemia. , 2022, , 831-851.e6.		0
424	Dramatic Recovery During IV-TPA Infusion: Time Course and Clinical Pattern. Stroke, 2001, 32, 370-370.	2.0	0
425	Combination of Thrombolytic Therapy with Antithrombotics and Neuroprotectants. , 2015, , 65-80.		0
426	Mobile Stroke Unit Hits the Road in Houston. US Neurology, 2015, 11, 59.	0.2	0
427	Stroke in Critically Ill Cancer Patients. , 2020, , 367-379.		0
428	Response by Sarraj et al to Letter Regarding Article, "Endovascular Thrombectomy for Acute Ischemic Strokes: Current US Access Paradigms and Optimization Methodology" Stroke, 2020, 51, e175-e176.	2.0	0
429	Clinical trials for cytoprotection in stroke. Neurotherapeutics, 2004, 1, 46-70.	4.4	0
430	Abstract WP148: The BRIDGE Project ( BRIDG ing the gap in strok <i>E</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 142 Jd (manag	2.0	0